A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
December 13, 2017
End Date
November 20, 2019
Administered By
Duke Cancer Institute
Awarded By
Bristol-Myers Squibb Company
Start Date
December 13, 2017
End Date
November 20, 2019